An IND is not an application the FDA approves. Under 21 CFR 312.40, an IND goes into effect 30 days after the agency receives it — unless the FDA tells you otherwise. Nobody sends a letter saying yes. The clock runs out, and you begin. Understanding that one inversion changes how you build the submission, because it means the review you are preparing for happens whether or not anyone talks to you.
Why the framing matters
If you believe an IND is an application, you write it to persuade. You wait for a decision. You plan a timeline with an approval milestone in it, and that milestone does not exist. If you understand it as a notice that starts a clock, you write it to withstand silence — because silence is the outcome you want, and silence means a reviewer read your package and found no reason to stop you.
This is also why an IND cannot be rescued by good writing. The reviewer is asking one question: is it reasonably safe to give this to humans? That question is answered by the toxicology, the manufacturing controls and the protocol's stopping rules — work that was either done properly a year ago or was not.
What is actually in it
- Nonclinical pharmacology and toxicology — evidence it is reasonably safe to begin human testing at your starting dose.
- Chemistry, manufacturing and controls — evidence you can make the thing consistently, and know what is in it.
- The clinical protocol and investigator information — what you will do to people, who will do it, and when you will stop.
Notice what is missing: efficacy. An IND is not where you argue the drug works. That comes later. Sponsors who load the IND with efficacy narrative are answering a question nobody asked, and it is usually a sign the safety package is thin.
The clock, precisely
Day 0 is the day FDA receives the submission, not the day you sent it. On day 30 the IND is in effect and you may dose, unless the agency has placed the study on clinical hold under 21 CFR 312.42. A hold can be imposed at any point in those 30 days, and it is communicated — you will not be left guessing. The agency may also tell you earlier that you may proceed, but that is a courtesy, not the mechanism.
So the honest project plan has no "IND approval" line in it. It has a submission date, 30 days, and a dosing date — plus the only real risk, which is a hold you could have predicted from your own data.
Frequently asked questions
Does the FDA approve an IND?
No. An IND goes into effect 30 days after FDA receives it unless the agency notifies the sponsor that the study is subject to clinical hold. There is no approval letter. Silence is the permission.
When can the 30-day clock be stopped?
At any point within the 30 days FDA may impose a clinical hold under 21 CFR 312.42. The sponsor may also be told earlier that the study may proceed, but the default outcome is the clock simply running out.
What actually goes in an IND?
Three data pillars plus the plan: nonclinical pharmacology and toxicology, chemistry and manufacturing information, and the clinical protocol with investigator information — the content required by 21 CFR 312.23.
Sources & further reading
- 21 CFR Part 312 — Investigational New Drug Application ecfr.gov
- FDA — Investigational New Drug (IND) Application fda.gov
This lesson is provided for general educational purposes and reflects the regulatory landscape as of its publication date. It is not legal or regulatory advice.
